HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?

Lexicon

Japan-Version NIH Initiative:
日本版NIH構想

The Column

It’s Moments Like These

Archives

Cabinet Approves Health, Medical Strategy(Jul.24)
Astellas Gears Up to Accelerate R&D(Jul.24)
Maruho Seeks Approval of Antibacterial Drug Ozenoxacin in Japan(Jul.24)
Japan Antidepressant Market Valued at 151 Billion Yen in 2022(Jul.24)
Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022(Jul.24)

Most Read

1.
Merck Serono Ja...
2.
Novartis, Maruh...
3.
Is Legal Regula...
4.
Ministry Panel ...
5.
Carna Shooting ...

News Calendar